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An arteriovenous ﬁstula is the current gold standard for chronic hemodialysis access. Tunneled catheters or synthetic
grafts have poorer outcomes and much higher risks of infection. This report presents the ﬁrst clinical use of a completely
biological, allogeneic, nonliving, and human tissue-engineered vascular graft. Tissue-engineered vascular grafts built from
allogeneic ﬁbroblasts were implanted as shunts in three hemodialysis patients. The tissue-engineered vascular graft was
stored for 9 months, without loss of mechanical strength. Implanted grafts showed no signs of degradation or dilation,
with time points up to 11 months. Results of panel-reactive antibody and cross-reactivity tests showed no evidence of
immune responses. (J Vasc Surg 2014;60:1353-7.)With the advent of cell culture, Weinberg and Bell1
and Zilla et al2 pioneered the idea of using cells to confer
physiologic qualities to prosthetic vascular grafts. L’Heur-
eux et al3,4 realized the original vision of Weinberg and
Bell by implanting the ﬁrst completely biological, living,
laboratory-grown graft in the high-pressure circulation
of a human, using an approach termed tissue engineering
by self-assembly. Clinical use of this autologous graft
showed remarkable results, with high primary patency
rates and no access-related infections. However, this
approach was encumbered by long production times
(average, 7.5 months) and the complexities associated
with delivering an autologous living product. The solu-
tion would be to transition to an allogeneic graft that is
available off-the-shelf.
This case report presents the ﬁrst human use of an allo-
geneic, tissue-engineered vascular graft to demonstrate the
feasibility and safety of transitioning to an allogeneic,
nonliving platform.
CASE REPORT
Three allogeneic Lifeline grafts (Cytograft Tissue Engineering,
Inc, Novato, Calif) were implanted as the brachial-axillary arteriove-
nous (AV) shunts for hemodialysis access. All patients (Allo 1, 2, andthe Department of General, Vascular, and Transplant Surgery,
edical University of Silesia, Katowicea; and Cytograft Tissue Engi-
ering, Inc, Novato.b
. is a beneﬁciary of the KOLUMB Fellowship Program granted by the
undation for Polish Science.
or conﬂict of interest: T.N.M. and N.L. are cofounders and signiﬁcant
ockholders in Cytograft Tissue Engineering, and N.D. is an employee of
ytograft.
rint requests: Nicolas L’Heureux, PhD, 3 Hamilton Landing, Ste 224,
ovato, CA 94949 (e-mail: nico@cytograft.com).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2013.08.0183) were dependent on a groin catheter for hemodialysis access at
the time of enrollment. The use of the Lifeline allogeneic graft
was recognized as a lifesaving procedure by the Medical University
of Silesia Bioethics Committee (Katowice, Poland). All patients
signed informed consents after the details and risks of the study
were described to them by the principal investigator.
Vessels were produced, as previously described,4 but were not
endothelialized, from cells of two informed male donors (aged
72 and 81 years) with end-stage renal disease. Vessels were dehy-
drated and stored at 80C for 6 (Allo 1) and 9 months (Allo
2 and 3) before use in this allogeneic safety trial. All graft lots
met release criteria previously established for the Lifeline graft.
Preimplantation burst pressure was 6407 6 633 and 5877 6
896 mm Hg for donor 1 (Allo 1) and donor 2 vessels (Allo 2
and 3), respectively (n ¼ 4 and 8). Suture retention was 261 6
20 gram-force (gf) and 319 6 48 gf, respectively (n ¼ 4 and
8). Predehydration values for burst and retention strength were
available for donor 2 vessels and were not signiﬁcantly different
from preimplant values (Student t-test, P < .05). Vessels from
a third donor (not implanted) were stored for 13 months,
without loss of strength (burst, 5066 6 777 mm Hg [n ¼ 8];
suture, 402 6 28 gf [n ¼ 8]). Preimplantation compliance
ranged from 2.0% to 3.1%/100 mm Hg (standard deviation,
0.4-0.7 [n ¼ 4 to 8]). The grafts were implanted using stan-
dard surgical techniques and required no special handling or
instrumentation.
Ultrasound examinations at days 2 and 4, at weeks 1, 2, and 4,
and monthly thereafter, showed no signs of graft degradation or
aneurysm formation (Figs 1-3). To demonstrate functionality,
the graft of patient Allo 1 was punctured for hemodialysis at
12 weeks, patient Allo 2 at 7 weeks, and patient Allo 3 at 8 weeks.
Blood ﬂows ranging from 1.3 to 1.9 L/min exceeded values for
good vascular access,6 and low dynamic venous pressures were
observed.
Immunologic and inﬂammatory blood markers were within
expected values. Total T-lymphocyte values, as well as CD4þ and
CD8þ subsets, were not inﬂuenced by the allogeneic implantation.
Panel reactive antibody (PRA) values at 4, 7, and 24 weeks were not
elevated (Allo 2 was not tested after 7 weeks, and Allo 1 was not1353
Fig 1. Graft of patient Allo 1, who was an 80-year-old woman with glomerulonephritis and coronary artery disease.
She had been receiving hemodialysis for 4.5 years, with previous failures of an ambilateral brachial-cephalic access
and of tunneled hemodialysis catheters in multiple locations, recurrent catheter infections and thromboses, hospi-
talizations for pneumonia, and lower limb deep venous thrombosis. A, Preimplantation hematoxylin and eosin
staining of the devitalized graft showed the same organization as a living graft,5 but with dense nuclear remnants in
the outer layers. B, Macroscopic view shows the implanted graft. Doppler ultrasound results at (C) 1 month, (D)
6 months, and (E) 11 months (composites from scan of entire length of graft) demonstrated no evidence of
aneurysm or wall degradation. At 11 months, restenosis was noted near the medial anastomosis (MA), 6 months
after percutaneous transluminal angioplasty. Flow was 1.3, 0.7, and 0.4 L/min at 1, 6, and 11 months, respectively.
Blood test results before implantation and after 2 and 7 weeks: white blood cells (normal reference range, 4.0-
10.0  103/mL): 5.1, 5.1, and 5.7  103/mL; lymphocytes (normal reference range, 20.5%-45.5%): 22.3%, 35.4%,
and 23.7%; T-lymphocytes (normal reference range, 59.0%-85.0%): 77.8%, 73.3%, and 78.3%; T-helper (CD3þ4þ)
cells (normal reference range, 29.0%-57.0%): 42.1%, 42.9%, and 40.7%; and T-suppressor/cytotoxic (CD3þ8þ)
lymphocyte (normal reference range, 11.0%-38.0%): 32.8%, 33.3%, and 32.9%. Donor-speciﬁc cross-match and
panel reactive antibody (PRA) test results at 7 and 24 weeks after implantation were negative. AA, Arterial anas-
tomosis; VA, venous anastomosis.
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Fig 2. Patient Allo 2 was a 60-year-old woman with coronary heart disease, hypertension, epilepsy, and polycystic
kidney disease. She had been receiving hemodialysis for 2.5 years. A previous Gracz arteriovenous ﬁstula failed to
mature, and tunneled catheters in bilateral jugular veins suffered recurrent thrombosis. Doppler ultrasound results at
6 weeks showed no evidence of aneurysm or wall degradation. The ﬂow was 1.9 L/min. Blood test results before
implantation and after 2 and 7 weeks: white blood cells (normal reference range, 4.0-10.0  103/mL): 8.7, 6.2, and
5.0 103/mL; lymphocytes (normal reference range, 20.5%-45.5%): 8.7%, 18.9%, and 17.4%; T-lymphocytes (normal
reference range, 59.0%-85.0%): 83.0%, 82.7%, and 88.2%; T-helper (CD3þ4þ) cells (normal reference range, 29.0%-
57.0%): 67.6%, 48.8%, and 64.0%; and T-suppressor/cytotoxic (CD3þ8þ) lymphocyte (normal reference range,
11.0%-38.0%): 13.5%, 32.5%, and 18.3%. Panel reactive antibody (PRA) before implantation and at 4 and 7 weeks after
was 0%. AA, Arterial anastomosis; MA, medial anastomosis; VA, venous anastomosis.
Fig 3. Patient Allo 3 was a 57-year-old woman with a history of diabetes, hypertension, and generalized atheroscle-
rosis. She had been receiving hemodialysis for >2 years. Previous radial-cephalic wrist and brachial-cephalic upper arm
access functioned only 10 days and 2.5 months, respectively. Vascular access for dialysis was with nontunneled and
tunneled catheters in the bilateral internal jugulars and the right femoral vein. She was hospitalized ﬁve times with
catheter infections during an 18-month period. Doppler ultrasound results after (A) 1 month and (B) 5 months show
no evidence of aneurysm or wall degradation. Visible remnant narrowing was seen 2 months after graft thrombectomy
and stent implantation. Flow was 1.8 L/min at 1 month and 0.6 L/min at 5 months. Blood test results before
implantation and after 2 and 7 weeks: white blood cell (normal reference range, 4.0-10.0  103/mL): 4.9, 6.6, and
5.4  103/mL; lymphocytes (normal reference range, 20.5%-45.5%): 29.4%, 28.0%, and 28.2%; T-lymphocytes
(normal reference range, 59.0%-85.0%): 79.3%, 73.3%, and 64.7%; T-helper (CD3þ4þ) lymphocytes (normal refer-
ence range, 29.0%-57.0%): 51.1%, 42.7%, and 32.8%; and T-suppressor/cytotoxic (CD3þ8þ) lymphocyte (normal
reference range, 11.0%-38.0%): 27.7%, 29.7%, and 19.1%. Panel reactive antibody (PRA) before implantation and at 4,
7, and 24 weeks after was 0%. AA, Arterial anastomosis; MA, medial anastomosis; VA, venous anastomosis.
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graft did not sensitize patients to human leukocyte antigen anti-
bodies. In addition, lymphocytotoxic cross-reactivity tests between
donor 1 and Allo 1 were negative at 7 weeks and at 6 months.
To ensure secondary graft patency, interventions were
required at 3 months in Allo 3 and at 5 months in Allo 1. Stenoses
of axillary and central veins were observed in both patients, partly
as a result of previous placements of catheters and shunts. Stenoses
at the medial anastomosis of the Lifeline graft were also noted.Mechanical thrombolysis and thrombectomy, followed with intra-
luminal balloon dilatation (Allo 1) or hybrid intervention with
surgical thrombectomy and axillary vein stenting (Allo 3), were
performed successfully. In all three patients, no symptoms of
graft-related infection with access site inﬂammation were observed,
which is consistent with previous observations from autologous
Lifeline graft implants.3,4
Patient Allo 1 ultimately lost graft patency 11 months after
implantation as the result of an automobile accident. The resulting
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who had previous access-related infections and C-reactive protein
levels >100 mg/L before implantation, showed systemic signs of
infection 6 weeks after implantation. A semipermanent catheter
was removed, leaving the Lifeline graft as the sole vascular access
for the last 7 days before the patient died of sepsis. Autopsy revealed
multiple renal abscesses with lung abscess. The graft of patient
Allo 3 functioned for 7 months and failed due to thrombosis.DISCUSSION
Infections of synthetic access devices are particularly
important complications for end-stage renal disease
patients aged >65 years. Infection in this population is
associated with a mortality rate hovering near 10% per
event.7 In contrast, ﬁstulas made from native vessels,
when available, show infection rates that are fourfold to
>12-fold lower than synthetic grafts.8 Similarly, allografts
or chemically treated xenografts have been shown to be
resistant to infection, although these grafts trigger inﬂam-
matory and immune responses.9-13 Not surprisingly,
cadaver-sourced homografts have been associated with
tissue degradation and mechanical instability linked to
immune responses.12,14,15 In addition, the use of alloge-
neic tissue for hemodialysis access has been shown to
trigger immunosensitization that can later preclude
patients from transplantation.10 However, a devitalized,
tissue-engineered graft is unlikely to be recognized as
a foreign material for two principal reasons:
First, the laboratory-grown graft is a simple tissue made
from human extracellular matrix (ECM) and ﬁbroblasts. It
lacks endothelial cells or other cells and structures prone to
trigger a speciﬁc immune system response,14 and the liter-
ature supports the concept that allogeneic ﬁbroblast-based
constructs are well tolerated by the immune system.16,17
Second, the graft does not undergo any chemical
modiﬁcations or denaturing steps that would damage the
ECM and initiate degradation through a nonspeciﬁc
immune system response.11 The lack of structural degrada-
tion, the stable levels of lymphocyte, and the negative PRA
results up to 24 weeks after implantation conﬁrmed the
innocuity of the allogeneic Lifeline graft. This is in contrast
to homografts that can raise PRA levels by as much as 80%
at 3 months.10
One concern with the use of a devitalized graft,
however, is its ability to withstand signiﬁcant mechanical
loads during the repopulation of the implant by the host’s
cells. The nonliving graft used in this study withstood the
harsh environment of the AV shunt, without signs of aneu-
rysm, for up to 11 months. The absence of cells may,
however, have adversely affected graft performance; for
example, delayed extravasation with slight bleeding into
the surrounding tissue at the site of previous needle place-
ment was noted. Although this type of complication is
common with synthetic grafts, it was not a signiﬁcant
observation with the autologous, living Lifeline graft used
previously.3,4 The lack of living cells in the graft wall may
slow the repair process at the puncture site. However,the size and complexity of this patient population is not
suitable for the determination of graft performance.
Although most efforts to produce nonliving transplant
tissues use detergent-based decellularization processes, this
study used a simple dehydration process.18 Because ﬁbro-
blasts in culture do not express major histocompatibility
complex class II antigens19,20 and no immunologically
active or xenogeneic cells are present, the rationale for
decellularization is clearly reduced. Moreover, that
detergent-based processing damages the ECM has been
well established.18 In previous human and animal studies
performed with a live graft, a dehydrated tissue layer sand-
wiched between endothelial cells and a living adventitia
layer proved to be extremely durable in vivo. This suggests
that this devitalization process did not compromise the
mechanical strength and preserved the natural structure
of the ECM.4,5
The presence of an antithrombogenic lining plays an
important role in preventing occlusive failures in lower-
ﬂow indications such as lower limb bypass or coronary
bypass. However, in the high-ﬂow setting of AV access,
an endothelium may not be required to maintain the
patency of a biologic graft. Although thrombogenic failures
were noted at 3 months in patient Allo 3 and at 5 months
in patient Allo 1, these longer-term complications appeared
to be secondary to stenosis.
CONCLUSIONS
The lack of graft degradation or immunosensitization
in all patients suggests that this allogeneic graft is safe
from an immune perspective. Taken together, this clinical
study suggests that neither the transition to allogeneic cells
nor the change to a nonliving graft adversely affected the
mechanical stability of the graft.
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